Daptomycin use in patients with osteomyelitis: A preliminary report from the EU-CORESM database

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 7, 2013, Pages 1642-1649

  Andrew Seaton, R ^a   Malizos, Konstantinos N ^b   Viale, Pierluigi ^c   Gargalianos Kakolyris, Panagiotis ^d   Santantonio, Teresa ^e   Petrelli, Enzo ^f   Pathan, Rashidkhan ^g   Heep, Markus ^g   Chaves, Ricardo L ^g  

^a GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF THESSALY   (Greece)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d G GENNIMATAS GENERAL HOSPITAL   (Greece)

^e UNIVERSITY OF FOGGIA   (Italy)

^f Ospedali Riuniti Marche Nord   (Italy)

^g NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Bone infections; Gram positive infections; Lipopeptides; Non interventional study; Prosthetic device infections

Indexed keywords

DAPTOMYCIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CHRONIC KIDNEY DISEASE; COXITIS; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOMYELITIS; POPULATION RESEARCH; PROSTHESIS INFECTION; RETROSPECTIVE STUDY; STAPHYLOCOCCUS INFECTION; TREATMENT FAILURE;

EID: 84879472754     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt067     Document Type: Article

References (32)

1. Lew DP, Waldvogel FA. Osteomyelitis. Lancet 2004; 364: 369-79.
2. Conterno LO, da Silva Filho CR. Antibiotics for treating chronic osteomyelitis in adults. Cochrane Database Syst Rev 2009; issue 3: CD004439.
3. Lazzarini L, Lipsky BA, Mader JT. Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials?. Int J Infect Dis 2005; 9: 127-38.
4. Fraimow HS. Systemic antimicrobial therapy in osteomyelitis. Semin Plast Surg 2009; 23: 90-9.
5. Marconescu P, Graviss EA, Musher DM. Rates of killing of methicillin-resistant Staphylococcus aureus by ceftaroline, daptomycin, and telavancin compared to that of vancomycin. Scand J Infect Dis 2012; 44: 620-2.
6. LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2004; 48: 4665-72.
7. Raad I, Hanna H, Jiang Y et al. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother 2007; 51: 1656-60.
8. Leite B, Gomes F, Teixeira P, et al. In vitro activity of daptomycin, linezolid and rifampicin on Staphylococcus epidermidis biofilms. Curr Microbiol 2011; 63: 313-7.
9. LaPlante KL, Woodmansee S. Activity of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus in an experimental model of endocarditis. Antimicrob Agents Chemother 2009; 53: 3880-6.
10. Traunmuller F, Schintler MV, Metzler J, et al. Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections. J Antimicrob Chemother 2010; 65: 1252-7.
11. Rouse MS, Piper KE, Jacobson M, et al. Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis. J Antimicrob Chemother 2006; 57: 301-5.
12. Lefebvre M, Jacqueline C, Amador G, et al. Efficacy of daptomycin combined with rifampicin for the treatment of experimental meticillin-resistant Staphylococcus aureus (MRSA) acute osteomyelitis. Int J Antimicrob Agents 2010; 36: 542-4.
13. Rouse MS, Steckelberg JM, Patel R. In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocarditis and bone and joint infection. Diagn Microbiol Infect Dis 2007; 58: 363-5.
14. John AK, Baldoni D, Haschke M, et al. Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: the importance of combination with rifampin. Antimicrob Agents Chemother 2009; 53: 2719-24.
15. Crompton JA, North DS, McConnell SA, et al. Safety and efficacy of daptomycin in the treatment of osteomyelitis: results from the CORE Registry. J Chemother 2009; 21: 414-20.
16. Larioza J, Girard A, Brown RB. Clinical experience with daptomycin for outpatient parenteral antibiotic therapy. Am J Med Sci 2011; 342: 486-8.
17. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52: e18-55.
18. Gonzalez-Ruiz A, Beiras-Fernandez A, Lehmkuhl H, et al. Clinical experience with daptomycin in Europe: the first 2.5 years. J Antimicrob Chemother 2011; 66: 912-9.
19. Martone WJ, Lindfield KC, Katz DE. Outpatient parenteral antibiotic therapy with daptomycin: insights from a patient registry. Int J Clin Pract 2008; 62: 1183-7.
20. Brandt CM, Sistrunk WW, Duffy MC, et al. Staphylococcus aureus prosthetic joint infection treated with debridement and prosthesis retention. Clin Infect Dis 1997; 24: 914-9.
21. Meehan AM, Osmon DR, Duffy MC, et al. Outcome of penicillin-susceptible streptococcal prosthetic joint infection treated with debridement and retention of the prosthesis. Clin Infect Dis 2003; 36: 845-9.
22. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med 2004; 351: 1645-54.
23. Byren I, Rege S, Campanaro E, et al. Randomized controlled trial of the safety and efficacy of daptomycin versus standard-of-care therapy for the management of patients with osteomyelitis associated with prosthetic devices undergoing two-stage revision arthroplasty. Antimicrob Agents Chemother 2012; 56: 5626-32.
24. Zimmerli W. Clinical practice. Vertebral osteomyelitis. N Engl J Med 2010; 362: 1022-9.
25. Chirouze C, Muret P, Berthier F, et al. Penetration of daptomycin into bone and joint. In: Abstracts of the Fifty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 2011. Abstract A1-1745. American Society for Microbiology, Washington, DC, USA.
26. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41: 1373-406.
27. Licitra C, Crespo A, Licitra D, et al. Daptomycin for the treatment of osteomyelitis and prosthetic joint infection: retrospective analysis of efficacy and safety in an outpatient infusion center. Internet J Infect Dis 2011; 9: doi:0.5580/215c.
28. Byren I, Bejon P, Atkins BL, et al. One hundred and twelve infected arthroplasties treated with 'DAIR' (debridement, antibiotics and implant retention): antibiotic duration and outcome. J Antimicrob Chemother 2009; 63: 1264-71.
29. Chakraborty A, Roy S, Loeffler J, et al. Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30min infusion or 2min injection. J Antimicrob Chemother 2009; 64: 151-8.
30. Fowler VGJ, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355: 653-65.
31. Durante-Mangoni E, Casillo R, Bernardo M, et al. High-dose daptomycin for cardiac implantable electronic device-related infective endocarditis. Clin Infect Dis 2012; 54: 347-54.
32. Novartis Europharm Ltd. Cubicin® (Daptomycin) Summary of Product Characteristics. 2012. http://www.medicines.org.uk/emc/medicine/17341 (18 January 2013, date last accessed).